Development of ANV419, a Novel CD122-Selective IL-2 Fusion Antibody With Potent CD8 T Cell & NK Cell Stimulatory Function

Time: 11:00 am
day: Day One


  • Delve into ANV419, a rationally designed non-alpha IL-2/anti-IL-2 antibody fusion protein and is engineered to lack CD25 binding activity but retains CD122 affinity comparable to native IL-2.
  • Learn how in vitro and animal studies demonstrate that ANV419 selectively proliferates CD8 T cells and NK cells over regulatory T cells resulting in potent anti-tumor activity.
  • Understand & discuss the favorable pre-clinical safety profile of ANV419 supports its further development in the ongoing Phase I dose escalation clinical trial.